Concerning metastatic tumours, conventional therapeutic methods such as multitarget tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors are extensively adopted; however, the therapeutic benefits are modest [4]. This evidence concerns the gene MTOR and neoplasm.